NCI SBIR provides
funding, mentoring & networking assistance
for small businesses with next-generation cancer technologies.
The SBIR & STTR Programs are one of the largest sources of early stage technology financing in the United States. We welcome entrepreneurs and small business leaders to this website to explore grant and contract funding opportunities.
Learn how NCI SBIR & STTR Programs have helped small businesses with funding awards that help advance cancer research.
AntiCancer, the San Diego-based biotechnology company, was awarded Phase I and II SBIR grants and contracts that have led to the commercialization of three cancer research tools: MetaMouse®, AngioMouse®, and OncoBrite®.
Developed LuViva, a non-invasive medical device designed to instantly detect cervical disease in a point-of-care setting with a $2.5 million Bridge Award.
If you are in a region affected by Hurricane Harvey and plan to submit an SBIR or STTR funding application for the deadline of 9/5/2017, please note the NIH Natural Disaster Policy (NOT-OD-17-106.)
NCI SBIR Director talks about NCI SBIR Contracts Solicitation in this interview with Cancer Currents. CLICK TO READ
FY18 HHS SBIR Contracts Solicitation is now available. Visit our Current Contracts page to view the list of 12 new contract topics.
The new Funding Opportunity Announcements (FOA) for 2017 Omnibus Soliciation are now available for both SBIR and STTR! Next receipt date is September 5, 2017. For more information, visit Omnibus Solicitations page.
New FOAs: Development of Highly Innovative Tools and Technology for Analysis of Single Cells (PA-17-147/148) [MORE INFO]